Teva expands in E Asia through JV with Korea's Handok
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries has signed an agreement to establish a new joint venture in South Korea with local firm Handok Pharmaceuticals, which will mark its first alliance in East Asian markets outside of Japan. The deal will enable Teva to tap into Korea's $14 billion pharmaceutical market through products including the multiple sclerosis drug Copaxone (glatiramer acetate injection) and its branded generics.